Sangamo Therapeutics Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Sangamo Therapeutics (SGMO) Misses Q1 EPS by 16c, Revenues Miss
May 8, 2019 4:03 PM EDTSangamo Therapeutics (NASDAQ: SGMO) reported Q1 EPS of ($0.41), $0.16 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $8 million versus the consensus estimate of $22.82 million.
"With recent encouraging clinical data in hemophilia A gene therapy and ex vivo gene-edited... More
